Scholarlink

Background <p>Nephrosclerosis has become an increasingly common underlying cause of renal replacement therapy worldwide. Hypertension is the primary cause of nephrosclerosis; however, other complex factors are believed to contribute to its onset and progression. In this study, we aimed to investigate whether hyperuricemia is a risk factor for the onset of chronic kidney disease and for progression of renal dysfunction. Additionally, we sought to determine whether the coexistence of hypertension and hyperuricemia exacerbates these risks.</p> Methods <p>A follow-up survey was conducted among 11,043 individuals aged 40–74 years in Tama City who underwent specific health checkups in 2016 and continued to receive health checkups for up to 6 years. We investigated the effects of hyperuricemia and hypertension at baseline on the subsequent development of proteinuria and decline in renal function.</p> Results <p>Elevated uric acid levels in both men and women were not associated with the onset of proteinuria; however, they were identified as risk factors for estimated glomerular filtration rate (eGFR) falling below 60 mL/min/1.73&#xa0;m² during follow-up, with cutoff values of 5.4&#xa0;mg/dL for men and 4.6&#xa0;mg/dL for women. Even in the presence of hypertension, elevated uric acid levels further increased the risk of eGFR falling below 60 mL/min/1.73&#xa0;m². Additionally, hyperuricemia was an associated factor for a &gt; 1.5-fold increase in serum creatinine levels during follow-up, with cutoff values of 7.1&#xa0;mg/dL for men and 5.2&#xa0;mg/dL for women. The coexistence of hyperuricemia and hypertension further amplified the risk of a &gt; 1.5-fold increase in serum creatinine levels.</p> Conclusion <p>The combination of hypertension and hyperuricemia appears to increase the risk of renal function deterioration due to nephrosclerosis.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hyperuricemia accelerates renal dysfunction due to hypertensive nephrosclerosis: the TAMA MED Project-CKD

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月27日

查看全文
  • Tomohiro Kaneko,
  • Eitaro Kodani,
  • Hitomi Fujii,
  • Kenta Sugino,
  • Yuri Kudo,
  • Norihiro Shibasaki,
  • Harufumi Ogino,
  • Hiroyuki Nakamura,
  • Hajime Sasabe,
  • Yutaka Tamura,
  • Masato Iwabu

摘要

Background

Nephrosclerosis has become an increasingly common underlying cause of renal replacement therapy worldwide. Hypertension is the primary cause of nephrosclerosis; however, other complex factors are believed to contribute to its onset and progression. In this study, we aimed to investigate whether hyperuricemia is a risk factor for the onset of chronic kidney disease and for progression of renal dysfunction. Additionally, we sought to determine whether the coexistence of hypertension and hyperuricemia exacerbates these risks.

Methods

A follow-up survey was conducted among 11,043 individuals aged 40–74 years in Tama City who underwent specific health checkups in 2016 and continued to receive health checkups for up to 6 years. We investigated the effects of hyperuricemia and hypertension at baseline on the subsequent development of proteinuria and decline in renal function.

Results

Elevated uric acid levels in both men and women were not associated with the onset of proteinuria; however, they were identified as risk factors for estimated glomerular filtration rate (eGFR) falling below 60 mL/min/1.73 m² during follow-up, with cutoff values of 5.4 mg/dL for men and 4.6 mg/dL for women. Even in the presence of hypertension, elevated uric acid levels further increased the risk of eGFR falling below 60 mL/min/1.73 m². Additionally, hyperuricemia was an associated factor for a > 1.5-fold increase in serum creatinine levels during follow-up, with cutoff values of 7.1 mg/dL for men and 5.2 mg/dL for women. The coexistence of hyperuricemia and hypertension further amplified the risk of a > 1.5-fold increase in serum creatinine levels.

Conclusion

The combination of hypertension and hyperuricemia appears to increase the risk of renal function deterioration due to nephrosclerosis.

Clinical trial number

Not applicable.